ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links0 made here, not in the record11 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT03260894Pembrolizumab (MK-3475)Plus Epacadostat vsStandard of Care in mRCC(KEYNOTE-679/ECHO-302)Incyte CorporationPhase 3 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSCarcinoma, Renal CellThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionParkinson Disease 4, Autoso…The registry's MeSH filing›Nov 14 · Rule based · MisfiledMisfiledDRUGSPembrolizumabIntervention entry›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundEpacadostatIntervention entry›Nov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedSunitinibIntervention entry›Nov 10 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPazopanibIntervention entry›Nov 10 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Pembrolizumab”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Background
Background · 1
Tested · 1

All judgments on this study

WhenLinkJudgeDecisionState
Nov 10PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 10EpacadostatClaude Opus 5.5TestedCurrent
Nov 10SunitinibClaude Opus 5.5ComparatorCurrent
Nov 10PazopanibClaude Opus 5.5ComparatorCurrent
Nov 14Carcinoma, Renal CellRule based · condition-kind ruleFinest filed termCurrent
Nov 14Parkinson Disease 4, Autosomal Dominant Lewy BodyRule based · condition-kind ruleMisfiledCurrent
Nov 18PembrolizumabRule based · role ruleTestedOverridden
Nov 18EpacadostatRule based · role ruleTestedAgrees
Nov 18SunitinibRule based · role ruleComparatorAgrees
Nov 18PazopanibRule based · role ruleComparatorAgrees
As of nowCarcinoma, Renal CellRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.